EXPERIMENTAL DESIGN : Using mouse models of EGFR -mutant lung cancer , we tested whether the combination of afatinib plus cetuximab delivered upfront to mice with TKI-na ve EGFR ( L858R ) - induced lung adenocarcinomas delayed tumor relapse and drug-resistance compared with single-agent TKIs .